Cargando…
A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
Programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD-1/PD-L1 inhibitors are associated with a low response rate and are only effective on a small number of patient...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985997/ https://www.ncbi.nlm.nih.gov/pubmed/33760188 http://dx.doi.org/10.3892/mmr.2021.12001 |
_version_ | 1783668354304704512 |
---|---|
author | Kong, Xianbin Lu, Peng Liu, Chuanxin Guo, Yuzhu Yang, Yuying Peng, Yingying Wang, Fangyuan Bo, Zhichao Dou, Xiaoxin Shi, Haoyang Meng, Jingyan |
author_facet | Kong, Xianbin Lu, Peng Liu, Chuanxin Guo, Yuzhu Yang, Yuying Peng, Yingying Wang, Fangyuan Bo, Zhichao Dou, Xiaoxin Shi, Haoyang Meng, Jingyan |
author_sort | Kong, Xianbin |
collection | PubMed |
description | Programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD-1/PD-L1 inhibitors are associated with a low response rate and are only effective on a small number of patients with cancer. Development of an anti-PD-1/PD-L1 sensitizer for improving response rate and effectiveness of immunotherapy is a challenge. The present study reviews the synergistic effects of PD-1/PD-L1 inhibitor with oncolytic virus, tumor vaccine, molecular targeted drugs, immunotherapy, chemotherapy, radiotherapy, intestinal flora and traditional Chinese medicine, to provide information for development of effective combination therapies. |
format | Online Article Text |
id | pubmed-7985997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-79859972021-03-23 A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy Kong, Xianbin Lu, Peng Liu, Chuanxin Guo, Yuzhu Yang, Yuying Peng, Yingying Wang, Fangyuan Bo, Zhichao Dou, Xiaoxin Shi, Haoyang Meng, Jingyan Mol Med Rep Review Programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD-1/PD-L1 inhibitors are associated with a low response rate and are only effective on a small number of patients with cancer. Development of an anti-PD-1/PD-L1 sensitizer for improving response rate and effectiveness of immunotherapy is a challenge. The present study reviews the synergistic effects of PD-1/PD-L1 inhibitor with oncolytic virus, tumor vaccine, molecular targeted drugs, immunotherapy, chemotherapy, radiotherapy, intestinal flora and traditional Chinese medicine, to provide information for development of effective combination therapies. D.A. Spandidos 2021-05 2021-03-16 /pmc/articles/PMC7985997/ /pubmed/33760188 http://dx.doi.org/10.3892/mmr.2021.12001 Text en Copyright: © Kong et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Kong, Xianbin Lu, Peng Liu, Chuanxin Guo, Yuzhu Yang, Yuying Peng, Yingying Wang, Fangyuan Bo, Zhichao Dou, Xiaoxin Shi, Haoyang Meng, Jingyan A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy |
title | A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy |
title_full | A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy |
title_fullStr | A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy |
title_full_unstemmed | A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy |
title_short | A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy |
title_sort | combination of pd-1/pd-l1 inhibitors: the prospect of overcoming the weakness of tumor immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985997/ https://www.ncbi.nlm.nih.gov/pubmed/33760188 http://dx.doi.org/10.3892/mmr.2021.12001 |
work_keys_str_mv | AT kongxianbin acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT lupeng acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT liuchuanxin acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT guoyuzhu acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT yangyuying acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT pengyingying acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT wangfangyuan acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT bozhichao acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT douxiaoxin acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT shihaoyang acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT mengjingyan acombinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT kongxianbin combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT lupeng combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT liuchuanxin combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT guoyuzhu combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT yangyuying combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT pengyingying combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT wangfangyuan combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT bozhichao combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT douxiaoxin combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT shihaoyang combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy AT mengjingyan combinationofpd1pdl1inhibitorstheprospectofovercomingtheweaknessoftumorimmunotherapy |